Cargando…
Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis
BACKGROUND: To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM). METHODS: All commercial health plan members in a large US managed care database with complete lipid panel results (HDL-C, LDL-C, TG) between 1/1/2006 and 12/31/2006 were identifi...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694778/ https://www.ncbi.nlm.nih.gov/pubmed/19450274 http://dx.doi.org/10.1186/1475-2840-8-26 |
_version_ | 1782168120447729664 |
---|---|
author | Toth, Peter P Zarotsky, Victoria Sullivan, Jane M Laitinen, Dave |
author_facet | Toth, Peter P Zarotsky, Victoria Sullivan, Jane M Laitinen, Dave |
author_sort | Toth, Peter P |
collection | PubMed |
description | BACKGROUND: To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM). METHODS: All commercial health plan members in a large US managed care database with complete lipid panel results (HDL-C, LDL-C, TG) between 1/1/2006 and 12/31/2006 were identified (N = 529,236). DM patients (N = 53,679) with mixed dyslipidemia were defined as having any 2 suboptimal lipid parameters (N = 28,728). Lipid treatment status 6 months pre- and post-index date was determined using pharmacy claims for any lipid therapy. RESULTS: Post-index, 41.1% of DM patients with 2 abnormal lipid parameters and 45.1% with 3 abnormal lipid parameters did not receive lipid-modifying treatment. Post-index treatment rates were 57.4%, 63.6%, and 66.4% for patients with LDL-C, HDL-C, and TG in the most severe quartiles, respectively. Statin monotherapy was the primary lipid-modifying regimen prescribed (54.8% and 47.8% of patients with any 2 and all 3 lipids not at goal, respectively). Less than 30% of treated patients received combination therapy. CONCLUSION: Over 40% of DM patients with mixed dyslipidemia received no lipid-modifying therapy during the follow-up period. Those who were treated were primarily prescribed statin monotherapy. This study suggests that DM patients are not being treated to ADA-suggested targets. |
format | Text |
id | pubmed-2694778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26947782009-06-11 Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis Toth, Peter P Zarotsky, Victoria Sullivan, Jane M Laitinen, Dave Cardiovasc Diabetol Original Investigation BACKGROUND: To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM). METHODS: All commercial health plan members in a large US managed care database with complete lipid panel results (HDL-C, LDL-C, TG) between 1/1/2006 and 12/31/2006 were identified (N = 529,236). DM patients (N = 53,679) with mixed dyslipidemia were defined as having any 2 suboptimal lipid parameters (N = 28,728). Lipid treatment status 6 months pre- and post-index date was determined using pharmacy claims for any lipid therapy. RESULTS: Post-index, 41.1% of DM patients with 2 abnormal lipid parameters and 45.1% with 3 abnormal lipid parameters did not receive lipid-modifying treatment. Post-index treatment rates were 57.4%, 63.6%, and 66.4% for patients with LDL-C, HDL-C, and TG in the most severe quartiles, respectively. Statin monotherapy was the primary lipid-modifying regimen prescribed (54.8% and 47.8% of patients with any 2 and all 3 lipids not at goal, respectively). Less than 30% of treated patients received combination therapy. CONCLUSION: Over 40% of DM patients with mixed dyslipidemia received no lipid-modifying therapy during the follow-up period. Those who were treated were primarily prescribed statin monotherapy. This study suggests that DM patients are not being treated to ADA-suggested targets. BioMed Central 2009-05-18 /pmc/articles/PMC2694778/ /pubmed/19450274 http://dx.doi.org/10.1186/1475-2840-8-26 Text en Copyright © 2009 Toth et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Investigation Toth, Peter P Zarotsky, Victoria Sullivan, Jane M Laitinen, Dave Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title | Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title_full | Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title_fullStr | Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title_full_unstemmed | Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title_short | Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis |
title_sort | dyslipidemia treatment of patients with diabetes mellitus in a us managed care plan: a retrospective database analysis |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694778/ https://www.ncbi.nlm.nih.gov/pubmed/19450274 http://dx.doi.org/10.1186/1475-2840-8-26 |
work_keys_str_mv | AT tothpeterp dyslipidemiatreatmentofpatientswithdiabetesmellitusinausmanagedcareplanaretrospectivedatabaseanalysis AT zarotskyvictoria dyslipidemiatreatmentofpatientswithdiabetesmellitusinausmanagedcareplanaretrospectivedatabaseanalysis AT sullivanjanem dyslipidemiatreatmentofpatientswithdiabetesmellitusinausmanagedcareplanaretrospectivedatabaseanalysis AT laitinendave dyslipidemiatreatmentofpatientswithdiabetesmellitusinausmanagedcareplanaretrospectivedatabaseanalysis |